Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is a promising novel therapeutics for B-cell acute lymphoblastic leukemia (BCP-ALL). MW :144.3 KD.